Selecta Biosciences Inc SELB:NASDAQ

Last Price$2.46NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.01(0.41%)
Bid (Size)$2.41 (1)
Ask (Size)$2.45 (5)
Day Low / High$2.36 - 2.51
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Selecta Biosciences Inc ( NASDAQ )

Price: $2.46
Change: +0.01 (0.41%)
Volume: 1.4 M
4:00PM ET 8/12/2022
 
 

22nd Century Group Inc ( NASDAQ )

Price: $1.82
Change: +0.02 (1.11%)
Volume: 1.5 M
4:00PM ET 8/12/2022
 
 

Alaunos Therapeutics Inc ( NASDAQ )

Price: $1.65
Change: -0.13 (7.30%)
Volume: 1.8 M
4:00PM ET 8/12/2022
 
 

Cymabay Therapeutics Inc ( NASDAQ )

Price: $4.01
Change: +0.27 (7.22%)
Volume: 464.4 K
4:00PM ET 8/12/2022
 
 

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $7.47
Change: +0.48 (6.87%)
Volume: 629.4 K
4:00PM ET 8/12/2022
 

Read more news Recent News

HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating
8:20AM ET 6/21/2022 MT Newswires

Selecta Biosciences (SELB) has an average rating of buy and price targets ranging from $4 to $13, according to analysts polled by Capital IQ. (MT Newswires...

Insider Buy: Selecta Biosciences
4:21PM ET 6/15/2022 MT Newswires

Carrie Smith Cox, Director, on June 13, 2022, executed a purchase for 130,000 shares in Selecta Biosciences (SELB) for $149,799. Following the Form 4...

Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating
8:51AM ET 6/14/2022 MT Newswires

Selecta Biosciences (SELB) has an average rating of buy and price targets ranging from $5 to $13, according to analysts polled by Capital IQ. (MT Newswires...

SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target
7:32AM ET 6/06/2022 MT Newswires

Selecta Biosciences (SELB) has an average rating of buy and price targets ranging from $6 to $13, according to analysts polled by Capital IQ. (MT Newswires...

Company Profile

Business DescriptionSelecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA. View company web site for more details
Address65 Grove Street
Watertown, Massachusetts 02472
Phone+1.617.923.1400
Number of Employees39
Recent SEC Filing08/08/202210-Q
President, Chief Executive Officer & DirectorCarsten Brunn
COO, Senior Vice President-Research & DevelopmentLloyd Johnston
Chief Financial & Accounting OfficerKevin Tan
Chief Scientific OfficerTakashi Kei Kishimoto

Company Highlights

Price Open$2.43
Previous Close$2.45
52 Week Range$0.65 - 4.70
Market Capitalization$375.7 M
Shares Outstanding152.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings246.00
Earnings per Share$0.09
Beta vs. S&P 500N/A
Revenue$903.0 K
Net Profit Margin24.86%
Return on Equity85.07%

Analyst Ratings as of 06/17/2022

Buy
8
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset